10-K: CRISPR Therapeutics Reports Increased Losses Amidst Pipeline Progress

CRISPR Therapeutics AG reported a significant increase in net loss for 2025, driven by higher collaboration expenses, despite advancing its gene-editing pipeline and securing key approvals for CASGEVY.

Summary

• CRISPR Therapeutics AG reported a net loss of $581.6 million for the year ended December 31, 2025, an increase from $366.3 million in 2024.
• Collaboration expense, net, significantly increased to $213.5 million in 2025 from $120.7 million in 2024, primarily due to the expiration of a deferral limit on CASGEVY program costs.
• Research and development expenses decreased by $25.4 million to $284.8 million in 2025, mainly due to decreased employee-related and facility costs, partially offset by increased sublicense and license fees.
• The company recognized $96.3 million in acquired in-process research and development expenses in 2025, related to the Sirius Agreement.
• Cash, cash equivalents, and marketable securities stood at $1,975.8 million as of December 31, 2025, up from $1,903.8 million in 2024.
• CASGEVY, the first approved CRISPR-based gene-editing therapy, received approvals in the United States, European Union, Great Britain, Canada, Switzerland, and certain Middle Eastern countries for severe SCD and TDT in patients 12 years and older.
• Positive Phase 3 data for CASGEVY in children aged 5-11 with SCD and TDT were presented in December 2025, showing 100% of evaluable SCD patients achieved VOC-free status for 12 months and 100% of evaluable TDT patients achieved transfusion independence for 12 months.
• CTX310, an in vivo gene-editing candidate for cardiovascular disease, demonstrated dose-dependent, durable reductions in ANGPTL3 (-73%), triglycerides (-55%), and LDL (-49%) in Phase 1 trials.
• Zugo-cel (CTX112), an allogeneic CAR T candidate, showed encouraging preliminary clinical data in autoimmune diseases (SLE, SSc, inflammatory myositis) and B-cell lymphomas, with a 70% complete response rate in R/R LBCL patients at the recommended Phase 2 dose.
• The company entered into a collaboration with Sirius Therapeutics in May 2025 for siRNA-based programs, including CTX611 for thromboembolic diseases, involving an upfront payment of $25.0 million cash and $70.0 million in common shares.
• CRISPR Therapeutics AG maintains a capital band authorizing the board to increase share capital up to CHF 3,142,094.52 until June 8, 2028, and conditional share capital for bonds and employee benefit plans.
• The company is subject to an ongoing patent infringement lawsuit initiated by ToolGen, Inc. in Q4 2025, alleging infringement by CASGEVY.
• The company expects its existing cash, cash equivalents, and marketable securities to fund operations for at least the next 24 months.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but cautiously optimistic report. While the increased net loss and collaboration expenses are concerning, the strong clinical data for CASGEVY and other pipeline candidates, coupled with a solid cash position, indicate significant progress and future potential in a high-growth, high-risk sector.

Positives

• CASGEVY, the first CRISPR-based gene-editing therapy, has received marketing approvals in multiple key jurisdictions (US, EU, GB, Canada, Switzerland, Middle East) for severe SCD and TDT.
• CASGEVY demonstrated strong efficacy in pivotal studies for children aged 5-11 with SCD and TDT, with 100% of evaluable patients achieving primary endpoints (VOC-free for SCD, transfusion independence for TDT).
• Longer-term data for CASGEVY in patients 12 years and older showed durable clinical benefits, with 100% of SCD patients achieving VOC-free status and 98.2% of TDT patients achieving transfusion independence.
• CTX310, an in vivo cardiovascular program, showed positive Phase 1 data with significant and durable reductions in ANGPTL3, triglycerides, and LDL, supporting advancement into Phase 1b.
• Zugo-cel (CTX112) demonstrated encouraging preliminary clinical data in autoimmune diseases and B-cell lymphomas, including a 70% complete response rate in R/R LBCL at the recommended Phase 2 dose.
• Zugo-cel exhibits increased manufacturing robustness and higher, more consistent CAR T cell production per batch due to next-generation edits.
• CTX611, an siRNA-based program, showed robust pharmacodynamic effects in Phase 1, with over 93% reduction in FXI levels and activity, sustained for up to six months.
• The company has a strong cash position of $1,975.8 million, expected to fund operations for at least the next 24 months.
• Strategic partnerships with Vertex and Sirius Therapeutics provide funding, expertise, and expanded therapeutic applications.
• The proprietary SyNTase editing platform represents a significant advance over prime editing systems, enabling greater efficiency and precision in gene correction.

Negatives

• Net loss significantly increased to $581.6 million in 2025 from $366.3 million in 2024, indicating a higher burn rate.
• Collaboration revenue decreased to $0 in 2025 from $35.0 million in 2024, impacting overall revenue.
• Collaboration expense, net, increased substantially to $213.5 million in 2025 due to the expiration of the deferral limit on CASGEVY program costs, leading to higher shared expenses.
• The company has a history of recurring losses and does not expect to be profitable in the foreseeable future.
• The company will need to raise substantial additional funding, which will dilute shareholders and may not be available on attractive terms.
• The company is subject to an ongoing patent infringement lawsuit by ToolGen, Inc. regarding CASGEVY, which could result in substantial damages or licensing requirements.
• Swiss corporate law provisions regarding capital management and dividend payments may limit financial flexibility and subject shareholders to withholding tax.

Risks

• Significant operating losses are anticipated to continue for the foreseeable future.
• Substantial additional funding will be needed, which could dilute shareholders if raised through equity, or impose restrictive covenants if through debt.
• Inability to raise capital when needed could force delays, reductions, or elimination of product development programs or commercialization efforts.
• Failure to advance product candidates to clinical development, obtain regulatory approval, or commercialize them, or significant delays in doing so, would materially harm the business.
• CRISPR/Cas9 gene editing is a relatively new technology, making development time and cost, and regulatory approval, difficult to predict.
• Undesirable side effects from product candidates or administration processes could delay or prevent regulatory approval, limit commercial potential, or result in negative consequences post-marketing.
• Delays or difficulties in patient enrollment for clinical trials could delay or prevent necessary regulatory approvals.
• Positive results from early preclinical studies or preliminary clinical trials are not necessarily predictive of later-stage results, risking failure to replicate success.
• Adverse public perception of gene editing and cellular therapy products may negatively impact demand or regulatory approval.
• Commercial success depends on market acceptance by physicians, patients, and third-party payors, which is uncertain.
• Significant competition exists in the biotechnology and pharmaceutical industries from companies with greater resources or alternative technologies.
• Reliance on Vertex Pharmaceuticals for the CASGEVY program means Vertex has significant control over its development and commercialization, potentially leading to delays or actions not in CRISPR's best interest.
• Gene editing and gene silencing products are novel and complex to manufacture, risking manufacturing problems or regulatory delays.
• Status as a Swiss corporation may limit capital management flexibility and cause distributions to be subject to Swiss withholding tax.
• Inability to obtain, maintain, or protect intellectual property rights related to proprietary gene editing technology and product candidates could hinder competition.
• The intellectual property landscape around gene editing, including CRISPR/Cas9, is highly dynamic, with third parties initiating legal proceedings alleging patent invalidity or infringement.
• Our engineered allogeneic T cell product candidates represent a novel approach with significant challenges, including donor material variability, potential for GvHD, and other serious adverse events.
• Regulatory authorities (FDA, MHRA, EMA) have demonstrated caution in regulating gene therapy, and ethical/legal concerns may result in additional regulations or restrictions.
• Failure to establish sales and marketing capabilities or enter into third-party agreements could hinder commercialization and revenue generation.
• Post-approval regulations could require substantial resource expenditure and limit manufacturing and marketing.
• Product liability and other product-related claims and lawsuits could lead to substantial liabilities.
• Failure to establish and maintain proper internal control over financial reporting could harm operating results.
• International operations present challenges due to diverse regulatory, financial, and legal requirements, currency rate changes, and geopolitical instability.
• Some in-licensed intellectual property may be subject to government march-in rights, reporting requirements, and preference for U.S.-based manufacturers.
• Disputes with licensors or licensees could adversely affect the business and lead to loss of important license rights.
• Inability to obtain or maintain necessary rights to product candidates or technologies through acquisitions and in-licenses could force abandonment of programs.
• Intellectual property litigation is expensive, time-consuming, and distracts personnel.
• Changes to patent law in the U.S. and other jurisdictions could diminish patent value.
• Non-compliance with procedural, document submission, and fee payment requirements for patents could reduce or eliminate patent protection.
• Intellectual property rights may not address all potential threats, allowing competitors to circumvent patents.
• Claims that employees, consultants, or advisors have wrongfully used or disclosed confidential information could arise.
• Failure to protect the confidentiality of trade secrets and other proprietary information could harm competitive position.
• Inadequate trademark protection could hinder name recognition.
• Broad discretion in the use of cash reserves may not lead to effective use.
• Sales of a substantial number of common shares could cause the share price to fall.
• No dividends are expected in the foreseeable future.
• As a Swiss corporation, shareholder rights may differ from U.S. jurisdictions, and Swiss legal provisions may limit flexibility.
• Unfavorable global economic conditions and uncertain geopolitical environment could adversely affect the business.
• Conditions in the banking system and financial markets could adversely affect operations and financial results.
• If securities analysts do not publish research or publish negative evaluations, the share price could decline.
• Disruptions at the FDA, SEC, and other government agencies could hinder timely development and commercialization.
• Increasing use of social media platforms presents risks of non-compliance and misinformation.
• Artificial intelligence presents risks including cybersecurity, data privacy, intellectual property, and regulatory challenges.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future as it advances its research and development programs, initiates preclinical and clinical trials, seeks regulatory approvals, and expands manufacturing capabilities. Existing cash, cash equivalents, and marketable securities are projected to fund operations for at least the next 24 months. The company intends to seek additional financing opportunities when market conditions are favorable to support long-term clinical development and commercialization.

Management Comments

• Our mission is to create transformative gene-based medicines for serious human diseases.
• We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both common and rare diseases.
• We continue to innovate on our platform to develop next-generation technologies that can enable new therapies, including delivery technologies and other gene editing technologies, like SyNTase.
• We are committed to implementing governance and control measures to mitigate risks related to artificial intelligence, but there can be no assurance that such measures will adequately prevent or mitigate adverse effects.

Industry Context

StockSavvy.ai notes that CRISPR Therapeutics AG operates at the forefront of the rapidly evolving gene-editing and cell therapy industries. The approval of CASGEVY marks a significant milestone, positioning the company as a leader in CRISPR-based therapeutics, a field still in its nascent stages with limited approved products. The company's diverse pipeline, including in vivo, CAR T, and regenerative medicine, reflects a broad strategy to address both rare and common diseases, leveraging its proprietary LNP and SyNTase platforms. The intense competition from large pharmaceutical and biotechnology companies, coupled with the dynamic intellectual property landscape, underscores the high-risk, high-reward nature of this sector. Regulatory caution around gene therapies and the increasing scrutiny of AI in healthcare are industry-wide challenges that CRISPR Therapeutics AG must navigate.

Comparison to Industry Standards

• CASGEVY's approval as the first CRISPR-based gene-editing therapy sets a new industry benchmark for genetic disease treatment, particularly for severe SCD and TDT, where previous curative options like allogeneic HSCT carried significant morbidity/mortality risks (e.g., compared to Zynteglo and Lyfgenia, which are lentiviral gene therapies with different risk profiles).
• The 100% VOC-free rate in SCD and 100% transfusion independence rate in TDT for CASGEVY in pediatric trials are exceptionally strong clinical outcomes, potentially surpassing the efficacy profiles of existing or developing therapies for these conditions.
• CTX310's Phase 1 data showing significant reductions in ANGPTL3, triglycerides, and LDL positions it competitively against other lipid-lowering therapies by aiming for a one-time, durable effect, potentially offering an advantage over chronic daily medications or frequent injections.
• Zugo-cel's preliminary complete response rate of 70% in R/R LBCL at the RP2D is competitive with, and in some cases, may exceed, response rates seen with approved autologous CD19-directed CAR T cell therapies (e.g., axicabtagene ciloleucel, lisocabtagene maraleucel), while offering the advantages of an allogeneic, 'off-the-shelf' product.
• CTX611's robust pharmacodynamic effects (over 93% reduction in FXI levels) suggest a differentiated approach to anticoagulation compared to Factor Xa inhibitors, potentially minimizing bleeding risk, a common challenge in the broader thromboembolic treatment market.

Corporate Governance

Legal Proceedings

• In the fourth quarter of 2025, ToolGen, Inc. initiated a lawsuit against the company and other third parties alleging patent infringement by CASGEVY of a ToolGen patent relating to CRISPR/Cas9 gene editing technology.
• The company is involved in quasi-litigation and inter partes administrative proceedings in various jurisdictions (U.S. Patent and Trademark Office, European Patent Office, Australia, Japan, China, India) involving its intellectual property estate, including the worldwide patent portfolio licensed from Dr. Charpentier.
• The CVC Group (Dr. Charpentier, University of California, University of Vienna) has been involved in interferences declared by the USPTO against Broad Institute, ToolGen, and MilliporeSigma regarding CRISPR/Cas9 patent inventorship and ownership.
• Opposition proceedings have been initiated in the European Patent Office against certain related European patents in-licensed from Dr. Charpentier, leading to some revocations and ongoing challenges.
• A third-party licensor formally engaged with the company in Q2 2025 regarding matters under their intellectual property contracts, leading to a probable loss accrual of $13.0 million in R&D expenses for 2025, with a total liability of $14.5 million as of December 31, 2025.

Related Party Transactions

• Collaboration agreements with Vertex Pharmaceuticals Incorporated and its affiliates (including ViaCyte) for hemoglobinopathies (CASGEVY), cystic fibrosis, Duchenne muscular dystrophy, myotonic dystrophy type 1, and diabetes.
• License agreements with Dr. Emmanuelle Charpentier for foundational CRISPR/Cas9 intellectual property, involving nominal clinical milestone payments, low single-digit royalties on sublicensing revenue, and low single-digit royalties on net sales.
• Collaboration, Option and License Agreement with Sirius Therapeutics and its affiliates for siRNA-based programs, involving an upfront cash payment of $25.0 million and issuance of 1,842,105 common shares (valued at $70.0 million) to Sirius, and future milestone and royalty payments.

Stakeholder Impact

• **Shareholders**: Increased net loss and the need for future capital raises could lead to further dilution. Ongoing IP litigation and market volatility pose risks to share price. However, strong clinical progress and approvals for CASGEVY, along with a robust pipeline, offer long-term growth potential.
• **Patients**: Continued development and approvals of gene-editing therapies like CASGEVY offer potential one-time functional cures for severe genetic diseases like SCD and TDT. Pipeline candidates for cardiovascular disease, autoimmune conditions, and diabetes could address significant unmet medical needs. Risks of side effects and regulatory delays remain.
• **Employees**: The company's growth strategy and focus on innovation provide opportunities, but the need for additional funding and potential workforce reductions if programs are curtailed could create uncertainty. Comprehensive compensation and benefits programs aim to attract and retain talent.
• **Collaborators (Vertex, Sirius)**: Continued collaboration is essential for pipeline advancement and commercialization. Financial terms, including profit/loss sharing and milestone payments, directly impact both parties. Disputes or changes in strategy by collaborators could affect program timelines and financial outcomes.
• **Regulatory Bodies**: The company's activities are subject to extensive and evolving regulations, particularly for novel gene therapies. Compliance with FDA, EMA, and other international standards is critical for approvals and market access. Ethical concerns around gene editing also influence regulatory scrutiny.

Next Steps

• Continue clinical trials for wholly-owned and partnered programs.
• Identify additional research programs and product candidates.
• Conduct preclinical studies to support IND applications and initiate clinical trials for new product candidates.
• Expand, maintain, enforce, and defend the intellectual property estate.
• Seek marketing approvals for product candidates that successfully complete clinical trials.
• Further develop gene editing and other proprietary technologies.
• Hire additional clinical, quality control, and scientific personnel.
• Establish, expand, or contract for manufacturing capabilities.
• Establish a sales, marketing, and distribution infrastructure for approved products.
• Address the ongoing ToolGen patent infringement lawsuit regarding CASGEVY.
• Monitor and adapt to evolving regulatory frameworks for gene therapy and AI.
• Consider additional financing opportunities to support long-term clinical development and commercialization.

Key Dates

Recommendation

CRISPR Therapeutics AG presents a compelling long-term growth story with its pioneering gene-editing technology and the first-ever approved CRISPR-based therapy, CASGEVY. The positive clinical data across its diverse pipeline, particularly for CASGEVY in pediatric populations and CTX310 in cardiovascular disease, demonstrates significant therapeutic potential. However, the substantial increase in net loss for 2025, driven by higher collaboration expenses, and the ongoing need for significant additional funding, introduce near-term financial headwinds and dilution risk. The complex and dynamic intellectual property landscape, including active litigation, also adds a layer of uncertainty. For a seasoned investor, the current valuation likely reflects much of the long-term potential, while the increased burn rate and IP risks warrant a 'hold' position, awaiting clearer paths to sustained profitability and resolution of key legal challenges before considering further accumulation.

Keywords

CRISPR, Gene Editing, CASGEVY, Sickle Cell Disease, Beta Thalassemia, CAR T, Autoimmune Disease, Oncology, In Vivo Gene Editing, siRNA, Regenerative Medicine, CTX310, Zugo-cel, CTX611, SyNTase, Biotechnology, Pharmaceuticals, Clinical Trials, Regulatory Approval, Intellectual Property, Vertex Pharmaceuticals, Sirius Therapeutics, Rare Diseases, Hemoglobinopathies, Cardiovascular Disease, Type 1 Diabetes, Refractory Hypertension, Alpha-1 Antitrypsin Deficiency, Thromboembolic Diseases